Literature DB >> 29947852

[Nephrology for urologists].

O Gross1, C Bramlage2.   

Abstract

By the very nature of things there are many overlaps between urology and nephrology. A close cooperation between the two disciplines is necessary for the benefit of the patient. From a nephrological perspective this article explains when and why participation of a nephrologist in treatment is recommended. In this context three essential points are explained: with respect to early recognition, renal hematuria, microalbuminuria, proteinuria, limited renal filtration function and glomerular filtration rate (GFR) are signs of renal disease; however, even patients with renal cysts should consult a nephrologist as early as possible due to the currently available treatment options. A delay in progression is possible and necessary for all chronic kidney diseases, independent of the trigger. Even when changes in the life style of the patient is troublesome and the adjustment of hypertension and hyperlipidemia sounds banal, their consistent implementation can result in a marked delay in the necessity for dialysis. The treatment of renal comorbidities is decisive and depends on the severity of the kidney disease. This includes the treatment of renal anemia, arterial hypertension, metabolic acidosis, uremic complications, electrolyte and water balance dysregulation and secondary hyperparathyroidism. By treating these comorbidities a marked reduction in the increased cardiovascular risk of nephrology patients can be achieved.

Entities:  

Keywords:  Hematuria; Kidney cysts; Nephroprotection; Proteinuria; Renal insufficiency

Mesh:

Year:  2018        PMID: 29947852     DOI: 10.1007/s00120-018-0691-6

Source DB:  PubMed          Journal:  Urologe A        ISSN: 0340-2592            Impact factor:   0.639


  4 in total

1.  Early angiotensin-converting enzyme inhibition in Alport syndrome delays renal failure and improves life expectancy.

Authors:  Oliver Gross; Christoph Licht; Hans J Anders; Bernd Hoppe; Bodo Beck; Burkhard Tönshoff; Britta Höcker; Simone Wygoda; Jochen H H Ehrich; Lars Pape; Martin Konrad; Wolfgang Rascher; Jörg Dötsch; Dirk E Müller-Wiefel; Peter Hoyer; Bertrand Knebelmann; Yves Pirson; Jean-Pierre Grunfeld; Patrick Niaudet; Pierre Cochat; Laurence Heidet; Said Lebbah; Roser Torra; Tim Friede; Katharina Lange; Gerhard A Müller; Manfred Weber
Journal:  Kidney Int       Date:  2011-12-14       Impact factor: 10.612

2.  Strict blood-pressure control and progression of renal failure in children.

Authors:  Elke Wühl; Antonella Trivelli; Stefano Picca; Mieczyslaw Litwin; Amira Peco-Antic; Aleksandra Zurowska; Sara Testa; Augustina Jankauskiene; Sevinc Emre; Alberto Caldas-Afonso; Ali Anarat; Patrick Niaudet; Sevgi Mir; Aysin Bakkaloglu; Barbara Enke; Giovanni Montini; Ann-Margret Wingen; Peter Sallay; Nikola Jeck; Ulla Berg; Salim Caliskan; Simone Wygoda; Katharina Hohbach-Hohenfellner; Jiri Dusek; Tomasz Urasinski; Klaus Arbeiter; Thomas Neuhaus; Jutta Gellermann; Dorota Drozdz; Michel Fischbach; Kristina Möller; Marianne Wigger; Licia Peruzzi; Otto Mehls; Franz Schaefer
Journal:  N Engl J Med       Date:  2009-10-22       Impact factor: 91.245

3.  Intensive Supportive Care plus Immunosuppression in IgA Nephropathy.

Authors:  Thomas Rauen; Frank Eitner; Christina Fitzner; Claudia Sommerer; Martin Zeier; Britta Otte; Ulf Panzer; Harm Peters; Urs Benck; Peter R Mertens; Uwe Kuhlmann; Oliver Witzke; Oliver Gross; Volker Vielhauer; Johannes F E Mann; Ralf-Dieter Hilgers; Jürgen Floege
Journal:  N Engl J Med       Date:  2015-12-03       Impact factor: 91.245

4.  Safety and Efficacy of the ACE-Inhibitor Ramipril in Alport Syndrome: The Double-Blind, Randomized, Placebo-Controlled, Multicenter Phase III EARLY PRO-TECT Alport Trial in Pediatric Patients.

Authors:  Oliver Gross; Tim Friede; Reinhard Hilgers; Anke Görlitz; Karsten Gavénis; Raees Ahmed; Ulrike Dürr
Journal:  ISRN Pediatr       Date:  2012-07-01
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.